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Most advanced glomerular diseases are characterized by
abnormal extracellular matrix (ECM) accumulation in the
glomeruli, and matrix metalloproteinases (MMPs) play a
pivotal role in ECM remodeling in various glomerular
diseases. The proto-oncogene, ets-1, is a transcription factor
regulating the expression of various matrix proteinases,
including MMP-1, MMP-3, and MMP-9. The goal of the
present study was to characterize the role of Ets-1 in the
progression of glomerular diseases. Overexpression of Ets-1
in cultured mesangial cells prevented transforming growth
factor (TGF)-b-induced inhibition of DNA-binding activity and
TGF-b-induced type I collagen production. In addition,
exogenous Ets-1 abolished TGF-b-induced collagen gel
contraction. The in vivo transfection of the ets-1 gene into
nephritic kidney resulted in the increases in glomerular
MMP-1, MMP-3, and MMP-9 mRNA, decreases in mesangial
ECM deposition, and attenuation of fibronectin extradomain
A (EDA) and type I collagen expression. In contrast,
knockdown of Ets-1 in glomeruli resulted in severe ECM
deposition in diseased glomeruli. In conclusion, Ets-1
promotes degradation of ECM proteins and is critical for
integral glomerular reorganization.
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Most advanced glomerular diseases are characterized by
increased accumulation of extracellular matrix (ECM) in
glomeruli. The normal glomerular ECM is primarily
composed of type IV collagen, laminin, fibronectin, and
sulfated proteoglycans, which are produced by mesangial cells
and epithelial cells.1,2 However, activated glomerular cells
secrete these matrix components in excessive amounts and
also secrete disease-specific matrix components, including
type I and type III collagens.3,4 Although the mechanisms of
ECM accumulation are not clearly understood, studies
suggest that ECM accumulation and progression to glomer-
ulosclerosis is associated with an imbalance between synthesis
and degradation of these matrix components.5 Further,
matrix metalloproteinase (MMP) may also play an important
role in ECM remodeling in various renal diseases.
The transcription factor ets-1 mediates embryogenesis,
angiogenesis, cell migration, and invasion.6–9 The Ets domain
binds to the Ets-binding motif GGAA/T in the cis-acting
element of target genes, and cooperates with the c-Fos/c-Jun
complex at the AP-1 site to induce expression of several
promoters.10 This motif is also present in the promoter
region of various other genes, including MMP-1, MMP-3,
MMP-9, urokinase-type plasminogen activator, and tissue
inhibitor of metalloproteinase-1.11–16 Ets-1 is expressed in
fibroblasts and endothelial cells6,8,9,13 and is transiently
expressed in endothelial cells during vascular development
in the embryo and during angiogenesis in the adult. Further,
inhibition of Ets-1 expression resulted in the inhibition
of endothelial cell migration, invasion, and angiogenic
activity.17
The ets-1 gene also contributes to kidney development by
activating forkhead-related transcription factor (FREAC), a
winged helix transcriptional factor detected during nephro-
genesis.18 However, the role of the renal Ets-1 expression
profile is controversial in the context of glomerular disease.
Naito et al.19 demonstrated that progression of rat crescentic
glomerulonephritis was associated with a significant increase
of Ets-1-positive cells, consisting mainly of epithelial and
endothelial cells but not of mesangial cells. In contrast,
Raffetseder et al.20 identified mesangial cells as the main
source of glomerular Ets-1 expression in the context of
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ant-Thy-1 nephritis. Further, the temporal increase of
mesangial Ets-1 expression correlated with mesangial cell
activation in experimental glomerulonephritis.20
Based on these data, it is not clear whether Ets-1 acts as a
protective regulator or as a progression factor for renal
disease. Thus, the goal of the present study was to
characterize the role of Ets-1 in the progression of glomerular
diseases.
RESULTS
Ets-1 prevents TGF-b-induced effects on mesangial cells
By utilizing ets-1-transfectant mesangial cells, DNA-binding
activity of a biotin-labeled double-stranded oligonucleotide
harboring the Ets-1 consensus-binding sequence was assessed
by electrophoretic mobility shift assay. As shown in Figure 1a,
TGF-b1 inhibited binding of a distinct nucleoprotein in
normal cultured mesangial cells in a dose-dependent manner.
Overexpression of Ets-1 prevented the inhibitory effect of
TGF-b1 on DNA binding.
In normal rat mesangial cells, treatment with TGF-b
resulted in increased expression of type I collagen in a dose-
dependent manner. However, overexpression of Ets-1 pre-
vented this effect (Figure 1b). Further, overexpression of Ets-1
also reduced the basal levels of type I collagen, suggesting that
the inhibitory effect of Ets-1 on ECM remodeling
may occur via a TGF-b-independent mechanism as well as
TGF-b-dependent pathway.
TGF-b1 significantly enhanced collagen gel contraction in
normal mesangial cells but not in cells overexpressing Ets-1
(Figure 1c). It has been reported that TGF-b1 increases
collagen matrix reorganization by increasing mesangial a1b1
integrin.21 These data suggest that overexpression of Ets-1
may prevent rearrangement of collagen matrix via inhibition
of TGF-b signaling.
Exogenous Ets-1 induces MMP expression and activity
Ets-1 was expressed very low, supposedly in endothelial and
epithelial cells, not in mesangial areas in normal kidney
(Figure 2a), whereas Ets-1 expression was significantly
increased not only in endothelial and epithelial cells but also
in some mesangial cells 7 days after Thy-1 antibody injection
(Figure 2b). We also investigated the glomerular ets-1 and the
matrix-related gene expressions in anti-Thy-1 glomerulo-
nephritis. Reverse transcriptase-polymerase chain reaction
(PCR) analysis showed that ets-1 and tissue inhibitor of
MMP-1 mRNA were increased on the day 3 and maintained
even on day 28. Although MMP-2 was upregulated for 1 week
and tapered by degrees, MMP-9, as well as MMP-1 and
MMP-3 (data not shown), did not show significant changes
in the course of anti-Thy-1 nephritis (Figure 2c). Mesangial
cells express a number of proteases that degrade ECM
proteins during glomerular matrix remodeling. Among them,
not MMP-2 but MMP-1, MMP-3, and MMP-9 contain
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Figure 1 | Ets-1 overexpression in cultured mesangial cells. Rat
mesangial cells were transfected with ets-1 cDNA, and established
ets-1 permanent transfectants. (a) In normal rat mesangial cells,
DNA-binding activity was reduced by TGF-b stimulation in a
dose-dependent manner, but ets-1 transfectant maintained the
DNA-binding activity. (b) In normal rat mesangial cells, the treatment
with TGF-b increased the expression of type I collagen. In contrast,
type I collagen expression was diminished below basal levels in ets-1
transfectants. (c) Although TGF-b significantly enhanced collagen
gel contraction in normal mesangial cells, gel contraction by
ets-1-transfectant mesangial cells was almost abolished.
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Figure 2 | Ets-1 and MMPs expression in nephritic glomeruli.
(a) Immunostaining of Ets-1 revealed that Ets-1 expression was very
low, supposedly in the nuclei of endothelial and epithelial cells, not in
mesangial cells of normal kidney, (b) but significantly increased in the
nuclei of not only endothelial and epithelial cells but also in
mesangial cells 7 days after Thy-1 antibody injection. Original
magnification  100. (c) PCR analysis showed that ets-1 and tissue
inhibitor of metalloproteinase-1 mRNA were increased on day 3
and maintained even on day 28. MMP-2 was upregulated for 1 week
and tapered by degrees. MMP-9 did not show significant changes
in the course of anti-Thy-1 nephritis.
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Ets-1-binding motif in their cis-acting element. These results
suggested that Ets-1 expression may not be sufficient in
glomerular matrix remodeling.
To examine the effect of overexpression of ets-1 in
mesangial cells, we transferred ets-1 gene into the nephritic
glomeruli by electroporation-mediated gene transfer, which
enables us to introduce genes into glomerular mesangial
cells.22 As Western blot analysis demonstrated that ets-1-gene
transfer markedly increased Ets-1 protein in glomeruli
compared with contralateral right kidneys (Figure 3a), we
next examined the effect of forced overexpression of Ets-1 on
the ECM remodeling in nephritic glomeruli.
Reverse transcriptase-PCR demonstrated that the levels of
mRNA of MMP-1, MMP-3, and MMP-9 were markedly
augmented in kidneys transfected with ets-1 compared with
the untreated contralateral kidneys (3.3-fold increase in
MMP-1, 5.2-fold in MMP-3, and 2.3-fold in MMP-9
compared with contralateral kidney) (Figure 3b). In contrast,
the expression of MMP-2 mRNA was almost equal when
comparing kidneys transfected with ets-1 and the untreated
contralateral kidneys.
MMP activity was assessed by glomerular gelatin zymo-
graphy, which demonstrated that glomerular MMP-3 and
MMP-9 activity was higher in kidneys transfected with ets-1
compared with the untreated contralateral kidneys (4.8-fold
increase in MMP-3 and 2.6-fold in MMP-9 compared with
contralateral kidney) (Figure 3c). In contrast, activity of
MMP-2 was equivalent when comparing the two groups.
Exogenous Ets-1 ameliorates histological changes
Histological analysis with periodic acid-Schiff staining
showed marked ECM accumulation in the untreated
contralateral kidneys (Figure 4a). In contrast, kidneys
transfected with ets-1 showed reduced ECM accumulation
(Figure 4b). Glomerular matrix score was significantly
reduced in ets-1-treated left kidneys compared with un-
treated contralateral right kidneys (2.7570.68 and
1.8870.67, in untreated and ets-1-treated, respectively;
Po0.01). Further, expression of smooth muscle a actin
(SMaA), fibronectin EDA, and type I collagen was much
higher in the glomeruli of untreated kidneys (Figure 5a, c, e)
than in ets-1-transfected kidneys (Figure 5b, d, f). Semi-
quantitative analysis demonstrated that SMaA-positive areas
were significantly decreased in ets-1-gene transfected group
compared with untreated contralateral group (16.975.6 and
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Figure 3 | Exogenous Ets-1 induces MMPs. (a) Western blot analysis
demonstrated that ets-1-gene transfer (lane 2) markedly increased
Ets-1 protein in glomeruli compared with untreated nephritic kidneys
(lane 1) or contralateral right kidneys (lane 3). (b) Reverse
transcriptase-PCR demonstrated that the levels of mRNA of MMP-1,
MMP-3, and MMP-9 were markedly augmented in ets-1-gene
transfected kidneys (lane 2) compared with those in untreated
nephritic kidneys (lane 1) or untreated contralateral nephritic kidneys
(lane 3). (c) Consistent with the results of (b), the glomerular activities
of MMP-3 and MMP-9 in ets-1-tranfected kidney (lane 2) were more
intense than those in untreated nephritic kidneys (lane 1) or
untreated contralateral nephritic kidneys (lane 3).
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Figure 4 | Effect of Ets-1 on the progression of anti-Thy-1
glomerulonephritis on day 7. Micrographs show representative
results of glomeruli stained with periodic acid-Schiff from untreated
contralateral nephritic kidney (a) and ets-1-treated kidney (b) Original
magnification  200.
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Figure 5 | Effect of Ets-1 on the ECM remodeling of anti-Thy-1
glomerulonephritis on day 7. Micrographs show representative
results of glomeruli stained with (a, b) SMaA, (c, d) fibronectin EDA,
and (e, f) type I collagen from (a, c, e) untreated contralateral
nephritic kidney and (b, d, f) ets-1-treated kidney. Original
magnification  200.
300 Kidney International (2006) 70, 298–305
o r i g i n a l a r t i c l e M Mizui et al.: Ets-1 and ECM remodeling
24.775.8%, respectively; Po0.01). Similar observation was
shown in fibronectin EDA (21.474.4 and 32.679.2;
Po0.001) and type I collagen (20.774.4 and 39.178.7%;
Po0.001) expression in ets-1-gene-transfected group com-
pared with untreated contralateral grouprespectively. We also
examined the involvement of ets-1 expression in normal
glomeruli by ets-1 gene transfer. Ets-1 expression in normal
glomeruli induced no significant histological changes (data
not shown).
Ets-1 reduces ECM proteins in nephritic glomeruli
Western blot analysis demonstrated that glomerular fibro-
nectin and type I collagen expression were increased in
untreated nephritic kidney but not in ets-1-transfected
kidneys (Figure 6). Laser densitometric analysis revealed that
fibronectin and type I collagen expression in glomeruli from
nephritic rats treated with ets-1 gene transfection was
reduced to 20 and 48% of those in untreated disease control,
respectively. These data suggest that Ets-1 is a potent
inhibitor of ECM accumulation. Decreased levels of ECM
proteins in glomeruli may result from the activation of the de-
gradative pathways (e.g. MMP), decreased collagen synthesis,
or both.
Knockdown of Ets-1 increases ECM deposition
Recent study demonstrated that the ets-1 gene is essential for
the normal development of mammalian kidneys and the
maintenance of glomerular integrity and that the Ets-1 may
act as an upstream regulator of the expression of FREAC-4
that is detected during kidney development. In the next step,
we transferred short synthetic interfering RNA for ets-1
(siEts-1) into the nephritic glomeruli to knockdown the ets-1
expression in glomeruli. Compared with the nephritic kidney
treated with siSCR (Figure 7), siEts-1-transfected nephritic
kidney represents a marked ECM accumulation in glomeruli
(Figure 3c) (2.5870.87 and 3.4270.73, in siSCR- and siEts-
1-treated, respectively; Po0.01), suggesting that excessive
ECM deposition progressed or ECM remodeling was delayed.
DISCUSSION
The present study suggests that Ets-1 acts as a protective
effector molecule and restores glomerular integrity. Over-
expression of Ets-1 prevented the TGF-b-induced reduction
in DNA-binding activity and prevented the TGF-b-induced
increase in type I collagen production in cultured mesangial
cells. In addition, exogenous ets-1 inhibited collagen gel
contraction induced by TGF-b, and in vivo transfection of
ets-1 into nephritic kidney resulted in increases in glomerular
MMP-1, MMP-3, and MMP-9 mRNA. Finally, ets-1-trans-
fected kidneys showed reduced mesangial ECM deposition
and reduced fibronectin EDA and type I collagen expression,
whereas knockdown of ets-1 in glomeruli resulted in severe
ECM deposition and diseased glomeruli.
The ECM is a network of macromolecules surrounding all
cells and comprised of collagens, proteoglycans, and multi-
adhensive matrix proteins. Controlled ECM synthesis,
deposition, and degradation occur during embryogenesis,
angiogenesis, and tissue repair. In contrast, only limited
turnover of the ECM occurs in the majority of normal adult
tissues. However, the balance between ECM synthesis and
degradation is disrupted in the context of various patho-
logical conditions, leading to abnormal ECM remodeling.
For example, excessive matrix synthesis and deposition is
characteristic of fibrotic diseases, such as glomerulosclerosis.
TGF-b is a potent renal fibrogenic growth factor23 that
upregulates ECM deposition via several different mechan-
isms, including stimulation of collagen synthesis, induction
of the profibrotic cytokines, and inhibition of MMP and
tissue inhibitor of metalloproteinase.24
In the present study, TGF-b reduced DNA-binding activity
of Ets-1 in a dose-dependent manner in normal mesangial
cells, but not in cells transfected with ets-1. In addition,
overexpression of Ets-1 inhibited TGF-b-induced type I
collagen production in cultured mesangial cells. Ets-1
interacts with the AP-1 (c-Fos/c-Jun) complex25 to regulate
various genes, including MMP-1 and MMP-3.16 Further,
elevated expression of Ets-1 in fibroblasts altered their
responses to TGF-b in favor of matrix degradation relative
to ECM deposition.26 Furthermore, the antagonistic effect
of Ets-1 against TGF-b1 was enhanced in the presence of
TGF-b1.26 We also examined the involvement of ets-1
expression in normal glomeruli by ets-1 gene transfer.
Transfection of ets-1 gene into normal glomeruli induced
no significant histological changes. Furthermore, ets-1 gene
transfection 7 days after disease induction induced no
significant glomerular changes at day 14. Our findings that
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Figure 6 | Glomerular fibronectin and type I collagen from
untreated nephritic kidneys (lane 1), ets-1-transferred kidneys
(lane 2) or contralateral kidneys (lane 3) were analyzed by
Western blot analysis. Glomerular fibronectin and type I collagen
were increased in untreated nephritic kidney, but not in
ets-1-transfected kidneys.
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Figure 7 | Knockdown of Ets-1 increases ECM deposition.
Morphological changes of a (a) siEts-1-treated or (b) siSCR-treated
nephritic kidney. Representative microphotographs of glomeruli
stained with periodic acid-Schiff were presented. Original magnification
 400.
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forced expression of Ets-1 on non-injured normal glomeruli
or later stage of self-limiting nephritic glomeruli induced no
significant changes were consistent with the previous
observations that Ets-1 induced MMPs activation were
apparent in the presence of TGF-b1.26 These data suggest
that under pathological conditions, overexpression of Ets-1
may antagonize the profibrotic effects of TGF-b, possibly via
AP-1-Ets-1-mediated prevention of TGF-b-Smad-dependent
gene expression. Thus, we postulate that Ets-1 is a potent
suppressor of TGF-b-induced genes. Of interest is that
overexpression of Ets-1 significantly affect the basal levels of
type I collagen, suggesting that the inhibitory effect of Ets-1
on ECM remodeling manifest itself in the context of TGF-b-
independent signaling pathway, as well as TGF-b signaling
pathway.
The present study demonstrated that exogenous Ets-1
prevented TGF-b-induced collagen gel contraction. The
collagen contraction process is composed of several phases
including cell migration, cell attachment to collagen fibers,
and reorganization of the surrounding collagen fibers into a
more dense and compact arrangement within the collagen
lattice.21 ECM remodeling requires proteases for matrix
degradation as well as cell adhesion via integrins. The a1b1
integrin is a collagen/laminin receptor that mediates collagen
matrix reorganization in various organs.21,27 TGF-b increases
collagen matrix reorganization by increasing mesangial a1b1
integrin, thereby leading to an increased adhesion of
mesangial cells to type I collagen and promotion of
glomerulosclerosis.21 In addition, TGF-b upregulates tissue
transglutaminase,24 leading to further activation of TGF-b
via crosslinking of the latent TGF-b-binding protein to the
ECM.28 Elevated levels of transglutaminase are associated
with fibrotic diseases, where its ability to crosslink ECM may
facilitate ECM deposition and promote resistance to the
action of MMP.29 Together with the present observations,
these data indicate that overexpression of Ets-1 in mesangial
cells may inhibit TGF-b-mediated mesangial cell association
with collagen fibers, thereby leading to abnormal ECM
reorganization.
Recently, it was reported that in vivo transfection of ets-1
antisense ODN resulted in an inhibition of angiogenesis
induced by the HGF gene in a rat ischemic hindlimb
model.30 We demonstrated that siEts-1-transfected nephritic
kidney represents a marked ECM accumulation in glomeruli
compared with the nephritic kidney treated with siSCR,
suggesting that the inhibition of Ets-1 induced excessive ECM
deposition or delayed ECM remodeling. Recent studies have
demonstrated that Ets-1 is essential for the normal develop-
ment of the mammalian kidneys and for maintenance of
glomerular integrity. Further, Ets-1 may act as an upstream
regulator of FREAC-4 expression during kidney develop-
ment. Indeed, the Ets-1 knockout mice exhibits various
glomerular abnormalities, including sclerosis, atrophy, and
markedly fewer and immature glomeruli.31 These results
support a protective role for Ets-1 in preserving the normal
structure of the kidney.
In order to prove the therapeutic effect of Ets-1 in vivo
mesangial cells, we transferred ets-1 gene into the mesangial
cells of the nephritic glomeruli by electroporation. We
demonstrated that ets-1 gene transfer markedly increased
Ets-1 protein in glomeruli, and thereby increased MMP
expression and activity in glomeruli. In addition, SMaA,
fibronectin EDA, and type I collagen expression was
significantly suppressed in ets-1-transfected nephritic kidneys
compared with untreated contralateral kidneys. Decreased
levels of ECM proteins in glomeruli may result from the
activation of the degradative pathways (e.g. MMP), decreased
collagen synthesis, or both. In human glomerular diseases,
increased TGF-b expression was observed in progressive
glomerular diseases and there was strong correlation
between the amount of TGF-b1 in biopsy and the degree
of fibrosis.23 TGF-b upregulates the synthesis of in-
dividual matrix components, including proteoglycans, col-
lagens, and glycoproteins.32 TGF-b also inhibits matrix
degradation by increasing the synthesis of protease inhibitors
and decreasing the synthesis of proteases.33 And TGF-b alters
the expression of integrins and modulates their relative
proportions on the cell surface in a manner that could
facilitate adhesion to the matrix.34 These evidences strongly
suggest that the inhibition of mesangial TGF-b expression
should be one of the crucial therapeutic strategies to prevent
the progression of renal fibrosis. Together with our in vitro
experiments, our in vivo experiments suggest that forced
overexpression of Ets-1 in glomeruli can suppress the ECM
proteins by blocking TGF-b pathways. Furthermore, we
demonstrated that ets-1 transfection induced glomerular
MMP-1, MMP-3, and MMP-9, which could degrade ECM
proteins.
Vascular endothelial growth factor and basic fibroblast
growth factor are angiogenic factors that induce expression of
Ets-1 in endothelial cells.13,35 Hepatocyte growth factor
(HGF), a potent angiogenic and antifibrotic factor, also
stimulated the expression of MMP-1 via induction of Ets-1 in
endothelial cells and vascular smooth muscle cells.30 Ets-1
plays an important role in angiogenesis by regulating the
expression of MMP and urokinase-type plasminogen acti-
vator13,17,36 and converting the endothelial cells to the
angiogenic phenotype via inducing the expression of integrin
b3.7 As cell migration is a multistep process that involves
adhesion, motility, and degradation of ECM, the migratory
cells may be regulated by several stimuli during the tissue
remodeling process. Mesangial cells were also demonstrated
to migrate and repopulate the glomerulus in a coordinated
manner after mesangial injury.37 Vascular endothelial growth
factor 38 and HGF39 are reported to have therapeutic roles in
various renal diseases. Of interest is that glomerular
proliferation was also inhibited in ets-1-transfected kidney.
Ets-1 was reported to have versatile effects on endothelial
cells during the course of angiogenesis; that is, one is for
cellular invasion, and the other is for the localized
apoptosis.40 This apoptotic effect of Ets-1 might inhibit the
glomerular proliferation. Taken together with our report, the
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induction of Ets-1 in mesangial cells may play a central role
in mesangial migration and remodeling.
These data indicate that forced expression of Ets-1 is a
potent inhibitor of ECM accumulation, both by decreasing
the synthesis of ECM proteins and by increasing the
degradation. In addition, Ets-1 in mesangial cells may inhibit
TGF-b-mediated mesangial cell association with collagen
fibers, thereby leading to abnormal ECM reorganization. The
fact that the antifibrotic effect of Ets-1 was enhanced in the
presence of TGF-b1 merits its therapeutic application into
fibrosis. Therefore, ets-1 gene transfer may be a feasible
therapeutic tool not only to inhibit the accumulation of ECM
proteins by blocking TGF-b signaling but also to promote
degradation of ECM proteins by inducing MMP. In
conclusion, Ets-1 maintains the plasticity of ECM proteins
to be degraded and plays crucial roles for executing integral
glomerular reorganization.
MATERIALS AND METHODS
Cell culture
Rat mesangial cells were isolated and cultured as described
previously41 and were maintained in RPMI 1640 (Sigma, St Louis,
MO, USA) containing 20% fetal bovine serum equilibrated with 5%
CO2–95% air at 371C. The cells at passage 6–8 were used. Mesangial
cells were transfected with ets-1 cDNA expression vector, pCNX2-
m-ets-1S by Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).
After incubation with RPMI 1640 containing 20% fetal bovine
serum, G418 (final concentration; 800mg/ml) (Sigma) was added to
the medium for the selection of permanent transfectants. Estab-
lished Ets-1 transfectants were maintained in RPMI 1640 with 20%
fetal bovine serum and G418.
Electrophoretic mobility shift assay
Quiescent subconfluent normal mesangial cells or Ets-1 transfec-
tants were treated with adding human recombinant TGF-b1 (1, 2,
and 5 ng/ml) for 24 h. After incubation, cells were washed twice with
ice-cold phosphate-buffered saline (PBS) without calcium and
magnesium and scraped in 10 ml of cold PBS. Nuclear extracts were
incubated with 100 ng/ml poly (d(I-C)) at room temperature for
5 min before adding the biotin-labeled transcription factor probe for
Ets-1/PEA3 (Panomics, Inc., Redwood City, CA, USA) . Probe
sequence was 50-GATCTCGAGCAGGAAGTTCGA and non-labeled
probe (cold probe) was used as control. The mixtures were separated
on a non-denaturing polyacrylamide gel and electrotransferred to
Biodyne B membrane (Pall, East Hills, NY, USA). After the
immobilization of bound oligos using UV crosslinker, detection
was performed with streproavidin–horseredish peroxidase conjugate.
Collagen gel contraction assay
Collagen gel contraction assays were performed to examine the
effect of Ets-1 on mesangial cells to reorganize and contract three-
dimensional collagen I gels.21 Quiescent normal or Ets-1-trans-
fectant mesangial cells were harvested at a concentration of 5 105
cells/ml in 0.5 ml of 1.25 RPMI 1640 for 30 min at 201C. The cell
suspension was mixed on ice with 0.5 ml of collagen I solution (59%
1.25 RPMI 1640, 40% rat tail collagen (3.75 mg/ml), 1% NaOH).
Collagen/cell suspension (500 ml each) was incubated in 24-well
plates (Costar, Cambridge, MA, USA) at 371C to polymerize the
collagen. The diameter of the hydrated gel was measured by use of
an inverted microscope at 24 h. To examine the effect of Ets-1 on
TGF-b-induced gel contraction, TGF-b1 (3.0 ng/ml) was added to
collagen/cell suspension before gel polymerization.
Short synthetic interfering RNA
Short synthetic interfering RNA (21 nucleotides long) to target ets-1
(siEts-1), and the scrambled genes (siSCR) were chemically
synthesized as 20 bis (acetoxyethoxy)-methyl ether-protected oligo-
nucleotides, deprotected, annealed, and purified by Dharmacon
Research (Lafayette, CO, USA). The sense and antisense strands of
siEts-1 and siSCR were: siEts-1, 50-ACGGAAGCGCAUCGAA
GCCdTdT-30 (sense), 50-GGCUUCGAUGCGCUUCCGUdTdT-30
(antisense); siSCR, 50-GUCAACUGUGGAGCAACACdTdT-30 (sense),
50-GUGUUGCUCCACAGUUGACdTdT-30 (antisense).
Northern blot analysis
We examined the effect of forced exogenous expression of Ets-1 on
TGF-b-induced type I collagen expression in vitro. TGF-b-treated
rat mesangial cells were rinsed twice with ice-cold PBS and scraped
with 1 ml of Trizol reagent (Invitrogen). Total RNA was extracted
according to the manufacturer’s protocol. Type I collagen was
labeled with [a-32P]dCTP (3000 Ci/mmol; Amersham Biosciences,
Buckingham, England) by the random priming method (Rediprime
II, Amersham Biosciences) and hybridization was carried out as
described previously.42
Experimental design in anti-Thy-1 GN
To determine the effect of Ets-1 on mesangial proliferative
glomerulonephritis, we employed an anti-Thy-1 model of glomer-
ulonephritis. All procedure was handled in a humane fashion in
accordance with the guidelines of the Animal Committee of Osaka
University. Six-week-old male s.d. rats were anesthetized by
intraperitoneal injection of pentobarbital (50 mg/kg) and anti-
Thy-1 model of glomerulonephritis was induced by an intravenous
injection of anti-Thy-1 monoclonal antibody, 1-22-3 (5mg/kg).43 On
day 3, the kidney was perfused with PBS via renal artery and then
ets-1 expression vector, pCNX2-m-ets-1S (200 mg in 0.5 ml of PBS),
siEts-1 (50mg), or siSCR (50 mg) was injected into left kidney in a
one shot manner (six rats in each group). The kidney was
sandwiched with tweezers-type of oval-shaped stainless electrode,
and electric pulses were delivered using an electric pulse generator
(Electro Square Porator T820; BTX, San Diago, CA, USA). The
shape of the pulse was a square wave and the voltage (75 V)
remained constant during the pulse duration. Three pulses of the
indicated voltage followed by three more pulses of the opposite
polarity were administrated to the kidney. Intra-pulse delay was 1 s
and the duration of the pulse was fixed at 100 ms.41
On day 7, treated left kidneys and untreated contralateral right
kidneys were perfused with cold autoclaved PBS, and samples of
tissues for light microscopy were fixed with 4% paraformaldehyde
overnight and dehydrated through a graded ethanol series and
embedded in paraffin. Histological sections (2mm) of the kidneys
were stained with periodic acid-Schiff reagent. For glomerular RNA
preparations, glomeruli were isolated from the pooled remaining
renal tissue by a standard sieving method.
Pathological changes in anti-Thy-1 nephritis model are hetero-
geneous among different glomeruli. Histological improvement of
the disease manifestations was quantitatively estimated. For each
samples, approximately 30 cortical glomerular cross-sections con-
taining vascular pole were evaluated in a blind fashion. Glomerular
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ECM deposition was graded semiquantitatively according to the
score described elsewhere. It ranged from 0 to 4; 0¼ glomerulus
without any deposition, 1¼ glomerulus with up to 25% deposition,
2¼ glomerulus with 26–50% deposition, 3¼ glomerulus with
51–75% deposition, 4¼ glomerulus with 76–100% deposition.
Glomerular expression of SMaA, fibronection EDA, and type I
collagen was evaluated by computerized image analysis using Mac
SCOPE program. In brief, selected glomeruli from each sample were
photographed and positive areas were highlighted on the captured
images. The area of positive staining relative to each glomerular area
was automatically calculated as a percentage with determined
threshold settings.
Immunohistochemistry
To examine the expression of Ets-1 and SMaA, immunohistochem-
istry staining was performed on tissues fixed in methyl Carnoy’s
solution. Tissue sections were preincubated with horse serum
diluted 1:20 with PBS for 30 min to block the nonspecific staining,
and then incubated with rabbit polyclonal antibody against Ets-1
(N-276, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) or
mouse immunoglobulin G anti-SMaA monoclonal antibodies
(Immunotech S.A., Cedex, Marseilles, France) for 60 min at room
temperature. The sections were then processed using an avidin-bio-
tinylated peroxidase complex method (Vectastain ABC kit, Vector
Laboratories, Inc., Burlingame, CA, USA) with diaminobenzidine
as the chromogen.
Treated kidneys were also examined by immunofluorescence.
Kidneys were fixed in ice-cold neutral-buffered 4% paraformalde-
hyde solution and embedded in O.C.T. compound (Tissue-Tek,
Sakura Finetek USA, Inc., Torrance, CA, USA). The cryostat sections
were stained with the monoclonal antibody against fibronectin EDA
(IST-9, Abcam, Cambridge, UK) and type I collagen (LSL Co.,
Tokyo, Japan). After blocking in 5% normal horse serum, sections
were incubated with first antibody for 1 h at room temperature,
followed by Texas red-conjugated anti-mouse immunoglobulin G
(1:200) (Vector Laboratories, Inc., Burlingame, CA, USA) for 30 min
at room temperature.
Reverse transcriptase-PCR
We examined the glomerular ets-1 and MMP mRNA expression
during the disease progression of anti-Thy-1 nephritis and
investigated the effect of forced exogenous expression of Ets-1 on
MMP expression in nephritic glomeruli. Isolated glomeruli from
Ets-1-transfected nephritic kidneys or untreated contralateral right
kidneys were homogenized with Polytron homogenizer (Kinematica,
Switzerland) in Trizol reagent after Ets-1 transfection. Total RNA
was extracted according to the manufacturer’s protocol. RNA was
denatured by heating and reverse-transcribed with reverse trans-
criptase. PCR was performed in the DNA thermal cycler (Applied
Biosystems, Foster City, CA, USA) with 100 mg of reaction mixture
and 5 U of Taq DNA polymerase. PCR products were run through
1% agarose gels.
The following primer pairs were synthesized and used for
amplification: for exogenously introduced ets-1, sense 50-
TCTGACTGACCGTACTC-30 and antisense 50-GGGTTGGCTCC
ATTAACCTG-30; for MMP-1, sense 50-TCTGACTGACCGTACTC-30
and antisense 50-GGGTTGGCTCCATTAACCTG-30; for MMP-2,
sense 50-TCTGACTGACCGTACTC-30 and antisense 50-GGGTTG
GCTCCATTAACCTG-30; for MMP-3, sense 50-TCTGACTGACCG
TACTC-30 and antisense 50-GGGTTGGCTCCATTAACCTG-30; for
MMP-9, sense 50-TCTGACTGACCGTACTC-30 and antisense 50-GG
GTTGGCTCCATTAACCTG-30; for tissue inhibitor of metallopro-
teinase-1, sense 50-TCTGACTGACCGTACTC-30 and antisense
50-GGGTTGGCTCCATTAACCTG-30.
Zymography
We also examined the effect of forced exogenous expression of Ets-1
on MMP activities in nephritic glomeruli by zymography. Collected
glomeruli were homogenized in 1 ml of lysis buffer containing
50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Nonidet-P40, 10%
glycerol, 1 mM phenylmethylsulfonyl fluoride, 1 mg/ml aprotinin,
1 mg/ml leupeptin, and 0.5 mM sodium orthovanadate by Polytoron
homogenizer at 41C. The soluble lysates were suspended in non-
reducing sample buffer, electrophoresed on a 7.5% sodium dodecyl
sulfate-polyacrylamide gel containing 2 mg/ml gelatin, washed in
renaturating buffer (50 nM Tris/HCl (pH 8.0), 2.5% Triton X-100),
and incubated overnight at 371C in 50 nM Tris/HCl (pH 8.0), 1 mM
ZnSO4, 5 nM CaCl2. Gels were methanol-fixed, stained with
Coomassie blue R-250 before destaining.
Western blot
To confirm the successful transfection of Ets-1 gene or examine the
effect of forced exogenous expression of Ets-1 on fibronectin EDA
and type I collagen expression in vivo, Western blot analysis was
performed. Collected glomeruli were homogenized in 1 ml of lysis
buffer at 41C. The soluble lysates were mixed 1:2 with 3 Laemmli
buffer and heated for 10 min at 951C. Lysates (20mg) were loaded
per lane, resolved by 15% sodium dodecyl sulfate-PAGE and
transferred onto a polyvinylidene difluoride membrane (Hybond-P
PVDF Membrane, Amersham Biosciences). Membranes were
blocked with 5% bovine serum albumin in Tris-buffered saline–Tw-
een 20 for 30 min at room temperature and then immunoblotted
with polyclonal antibodies against Ets-1 (N-27, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), fibronectin EDA (LSL Co,
Tokyo, Japan), and type I collagen (IST-9, abcam, Cambridge, UK),
in blocking buffer for 1 h at room temperature. The primary
antibodies were detected using horseradish peroxidase-conjugated
goat anti-rabbit and visualized with SuperSignal West Pico
Chemiluminescent Substrate (PIERCE, Rockford, IL, USA) accor-
ding to the manufacturer’s directions. The blots were exposed to
X-ray film (Hyperfilm, Amersham Biosciences).
Statistical study
All values are expressed as means7s.d. Statistical significance
(defined as Po0.01) was evaluated using the one-way analysis of
variance.
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